E. Vuillemin

1.2k total citations
43 papers, 916 citations indexed

About

E. Vuillemin is a scholar working on Hepatology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, E. Vuillemin has authored 43 papers receiving a total of 916 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hepatology, 13 papers in Epidemiology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in E. Vuillemin's work include Liver Disease Diagnosis and Treatment (12 papers), Liver Disease and Transplantation (10 papers) and Immunotherapy and Immune Responses (4 papers). E. Vuillemin is often cited by papers focused on Liver Disease Diagnosis and Treatment (12 papers), Liver Disease and Transplantation (10 papers) and Immunotherapy and Immune Responses (4 papers). E. Vuillemin collaborates with scholars based in France, Switzerland and United States. E. Vuillemin's co-authors include Paul Calès, Frédéric Oberti, Vincent Croquet, Marie Christine Rousselet, Daniel Chappard, Frédéric Moal, M. Namer, D. Serin, Thierry Lesimple and Véronique Dièras and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Hepatology.

In The Last Decade

E. Vuillemin

42 papers receiving 879 citations

Peers

Countries citing papers authored by E. Vuillemin

Since Specialization

Citations

This map shows the geographic impact of E. Vuillemin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Vuillemin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Vuillemin more than expected).

Fields of papers citing papers by E. Vuillemin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Vuillemin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Vuillemin. The network helps show where E. Vuillemin may publish in the future.

Co-authorship network of co-authors of E. Vuillemin

This figure shows the co-authorship network connecting the top 25 collaborators of E. Vuillemin. A scholar is included among the top collaborators of E. Vuillemin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Vuillemin. E. Vuillemin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Diagnostic Accuracy of a Noninvasive Test for Detection of Helicobacter pylori and Resistance to Clarithromycin in Stool by the Amplidiag H. pylori+ClariR Real-Time PCR Assay 2020 ·Journal of Clinical Microbiology ·Maxime Pichon, (unknown), Thierry Barrioz, Chloé Plouzeau, Vincent Croquet, (unknown), (unknown), E. Vuillemin, (unknown), (unknown), Philippe Vasseur, (unknown), (unknown), (unknown), Julie Cremniter, Lauranne Broutin, Anthony Michaud, Christine Silvain, Christophe Burucoa	68
2	Gestational choriocarcinoma associated with a germline TP53 mutation 2017 ·Familial Cancer ·Anne‐Claire Bréhin, (unknown), Gaëlle Bougeard, (unknown), (unknown), Aude Lamy, (unknown), (unknown), Capucine Delnatte, E. Vuillemin, (unknown), Sylvie Odent, Jean‐Christophe Sabourin, François Golfier, Thierry Frébourg	3
3	Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study) 2016 ·Annals of Oncology ·J. Guigay, Emmanuel Chamorey, (unknown), F. Mornex, M. Degardin, M. Alfonsi, Laurence Digue, (unknown), Xavier Artignan, L. Cals, Sandrine Faivre, E. Vuillemin, Frédéric Rolland, A. Timochenko, E. Babin, (unknown), A Toby Prevost, (unknown), Frédéric Peyrade, Christophe Le Tourneau	3
4	Cetuximab Relative Dose Intensity (Rdi) in Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (Scchn): First Observational Prospective Study in Unselected Patients (Direct Trial) 2014 ·Annals of Oncology ·J. Guigay, Frédéric Peyrade, (unknown), (unknown), (unknown), Laurence Digue, (unknown), M. Degardin, M. Alfonsi, Xavier Artignan, L. Cals, Sandrine Faivre, E. Vuillemin, Frédéric Rolland, A. Timochenko, E. Babin, A Toby Prevost, (unknown), Emmanuel Chamorey, C. Le Tourneau	5
5	Hemodynamic Effects of Acute and Chronic Administration of Vapreotide in Rats with Cirrhosis 2003 ·Digestive Diseases and Sciences ·Nary Veal, Frédéric Moal, Frédéric Oberti, E. Vuillemin, Paul Calès	4
6	Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer 2003 ·European Journal of Cancer ·P. Fumoleau, R. Largillier, (unknown), Véronique Dièras, Hubert Orfeuvre, Thierry Lesimple, Stéphane Culine, B. Audhuy, D. Serin, H. Curé, E. Vuillemin, Jean‐François Morère, François Montestruc, (unknown), M. Namer	247
7	Fractal dimension can distinguish models and pharmacologic changes in liver fibrosis in rats 2002 ·Hepatology ·Frédéric Moal, Daniel Chappard, Jianhua Wang, E. Vuillemin, (unknown), Marie Christine Rousselet, F. Oberti, Paul Calès	43
8	Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension 2002 ·Journal of Hepatology ·Vincent Croquet, Frédéric Moal, Nary Veal, Jianhua Wang, Frédéric Oberti, J. Roux, E. Vuillemin, Yves Gallois, Olivier Douay, Daniel Chappard, Paul Calès	84
9	Prothrombin index is an indirect marker of severe liver fibrosis 2002 ·European Journal of Gastroenterology & Hepatology ·Vincent Croquet, E. Vuillemin, Catherine Ternisien, Christophe Pilette, F. Oberti, Yves Gallois, Marc Trossaërt, Marie Christine Rousselet, Daniel Chappard, Paul Calès	60
10	[Non-steroidal antiinflammatory drug-related duodenal diaphragm treated by diathermic endoscopic incision]. 2002 ·PubMed ·E. Vuillemin, (unknown), (unknown), (unknown)	1
11	Chronic hemodynamic effects of a new liver specific no donor (V-PYRRO/NO) in bile duct ligated (BDL) rats 2000 ·Gastroenterology ·Frédéric Moal, E. Vuillemin, (unknown), Nary Veal, F. Oberti, Paul Calès	2
12	Spleno-renal shunt blood flow is an accurate index of collateral circulation in different models of portal hypertension and after pharmacological changes in rats 2000 ·Journal of Hepatology ·Nary Veal, Frédéric Oberti, Frédéric Moal, E. Vuillemin, (unknown), Mehdi Kaassis, Christophe Pilette, Paul Calès	12
13	[Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha]. 1998 ·PubMed ·H Rifflet, E. Vuillemin, Frédéric Oberti, Philippe Duverger, Pekka Laine, (unknown), Paul Calès	46
14	Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma 1996 ·Annals of Oncology ·J.M. Tourani, Virginie Lucas, Didier Mayeur, B Dufour, Mario Di Palma, C Boaziz, P. Grise, C. Varette, (unknown), Éric Pujade-Lauraine, (unknown), (unknown), M. Untereiner, E. Vuillemin, S. Merran, Jean‐Marie Andrieu	28
15	A Phase II Study of Tamoxifen Combined with Cisplatin-Interleukin 2 and Alpha-Interferon in Metastatic Melanoma 1995 ·American Journal of Clinical Oncology ·(unknown), Olivier Rixe, E. Vuillemin, A. Benhammouda, Christian Borel, Giancarlo Ghironzi, E. Mularoni, C.R. Franks, G Auclerc, C. Soubrane, Pierre Banzet, M Weil, D. Khayat	6
16	Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma 1994 ·Clinical & Experimental Immunology ·Roger Mouawad, (unknown), Olivier Rixe, A. Benhammouda, E. Vuillemin, M Weil, D. Khayat, C. Soubrane	6
17	Psychological side effects induced by interleukin‐2/α interferon treatment 1994 ·Psycho-Oncology ·M. J. Smith, Roger Mouawad, E. Vuillemin, A. Benhammouda, C. Soubrane, D. Khayat	4
18	Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. 1993 ·Journal of Clinical Oncology ·D. Khayat, Christian Borel, J.M. Tourani, A. Benhammouda, E Antoine, Olivier Rixe, E. Vuillemin, (unknown), L Thill, (unknown)	116
19	Chemoimmunotherapy of metastatic malignant melanoma The Salpétrière Hospital (SOMPS) experiences 1993 ·European Journal of Cancer ·D. Khayat, E Antoine, Olivier Rixe, J.M. Tourani, E. Vuillemin, (unknown), A. Benhammouda, L Thill, C.R. Franks, G Auclerc, M Weil, (unknown), Pierre Banzet	6
20	[Seraspenide (acetylSDKP): phase I-II trial study of inhibitor of hematopoiesis protects against toxicity of aracytine and ifosfamide monochemotherapies]. 1992 ·PubMed ·Patrice Carde, Claude Chastang, Emanuel Gonçalves, (unknown), E. Vuillemin, (unknown), (unknown), Anne Vekhoff, F Isnard, (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact